{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:22:25Z","timestamp":1793323345705,"version":"4.5.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The 2-drug regimen dolutegravir (DTG) + lamivudine (3TC) is indicated for treatment-naive adults with human immunodeficiency virus type 1 (HIV-1). We present efficacy and safety of switching to DTG\/3TC in virologically suppressed individuals.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>TANGO is an open-label, multicenter, phase 3 study that randomized adults (1:1, stratified by baseline third agent class) with HIV-1 RNA &amp;lt;50 copies\/mL to switch to once-daily fixed-dose DTG\/3TC or remain on a tenofovir alafenamide (TAF)\u2013based regimen. The primary end point was proportion of participants with HIV-1 RNA \u226550 copies\/mL at week 48 (US Food and Drug Administration Snapshot algorithm) in the intention-to-treat\u2013exposed population (4% noninferiority margin).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>743 adults were enrolled; 741 received \u22651 dose of study drug (DTG\/3TC, N = 369; TAF-based regimen, N = 372). At week 48, proportion of participants with HIV-1 RNA \u226550 copies\/mL receiving DTG\/3TC was 0.3% (1\/369) vs 0.5% (2\/372) with a TAF-based regimen (adjusted treatment difference [95% confidence interval], \u22120.3 [\u22121.2 to .7]), meeting noninferiority criteria. No participants receiving DTG\/3TC and 1 receiving a TAF-based regimen met confirmed virologic withdrawal criteria, with no emergent resistance at failure. Drug-related grade \u22652 adverse events and withdrawals due to adverse events occurred in 17 (4.6%) and 13 (3.5%) participants with DTG\/3TC and 3 (0.8%) and 2 (0.5%) with a TAF-based regimen, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>DTG\/3TC was noninferior in maintaining virologic suppression vs a TAF-based regimen at week 48, with no virologic failure or emergent resistance reported with DTG\/3TC, supporting it as a simplification strategy for virologically suppressed people with HIV-1.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT03446573.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciz1243","type":"journal-article","created":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T20:08:58Z","timestamp":1577995738000},"page":"1920-1929","source":"Crossref","is-referenced-by-count":262,"title":["Efficacy and Safety of Switching to Dolutegravir\/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide\u2013Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study"],"prefix":"10.1093","volume":"71","author":[{"given":"Jean","family":"van Wyk","sequence":"first","affiliation":[{"name":"ViiV Healthcare, Brentford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fa\u00efza","family":"Ajana","sequence":"additional","affiliation":[{"name":"Centre Hospitalier de Tourcoing, Tourcoing, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Bisshop","sequence":"additional","affiliation":[{"name":"Holdsworth House Medical Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"De Wit","sequence":"additional","affiliation":[{"name":"CHU Saint-Pierre, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olayemi","family":"Osiyemi","sequence":"additional","affiliation":[{"name":"Triple O Research Institute PA, West Palm Beach, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Portilla Sogorb","sequence":"additional","affiliation":[{"name":"Hospital General Universitario de Alicante, Alicante, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Routy","sequence":"additional","affiliation":[{"name":"McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wyen","sequence":"additional","affiliation":[{"name":"Praxis am Ebertplatz, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounir","family":"Ait-Khaled","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Brentford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Claudia","family":"Nascimento","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Brentford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A","family":"Pappa","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruolan","family":"Wang","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Wright","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Stockley Park, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan R","family":"Tenorio","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Wynne","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Aboud","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Brentford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J","family":"Gartland","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly Y","family":"Smith","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,1,6]]},"reference":[{"key":"2020110510415985900_CIT0001","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/S2352-3018(17)30066-8","article-title":"Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies","volume":"4","author":"Trickey","year":"2017","journal-title":"Lancet HIV"},{"key":"2020110510415985900_CIT0002","doi-asserted-by":"crossref","first-page":"113","DOI":"10.18683\/germs.2017.1115","article-title":"2-Drug regimens in HIV treatment: pharmacological considerations","volume":"7","author":"Back","year":"2017","journal-title":"Germs"},{"key":"2020110510415985900_CIT0003","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s40265-016-0553-8","article-title":"Two-drug treatment approaches in HIV: finally getting somewhere?","volume":"76","author":"Kelly","year":"2016","journal-title":"Drugs"},{"key":"2020110510415985900_CIT0004","volume-title":"Juluca","year":"2019"},{"key":"2020110510415985900_CIT0005","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies","volume":"391","author":"Llibre","year":"2018","journal-title":"Lancet"},{"key":"2020110510415985900_CIT0006","volume-title":"Dovato","year":"2019"},{"key":"2020110510415985900_CIT0007","volume-title":"Dovato","year":"2019"},{"key":"2020110510415985900_CIT0008","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"2020110510415985900_CIT0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2016.07.006","article-title":"Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance","volume":"239","author":"Brenner","year":"2017","journal-title":"Virus Res"},{"key":"2020110510415985900_CIT0010","article-title":"Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials","author":"Cahn","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020110510415985900_CIT0011","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/jac\/dky467","article-title":"Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL)","volume":"74","author":"Joly","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2020110510415985900_CIT0012","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/cid\/cix1131","article-title":"Dolutegravir plus lamivudine maintains human immunodeficiency virus-1 suppression through week 48 in a pilot randomized trial","volume":"66","author":"Taiwo","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020110510415985900_CIT0013","article-title":"ViiV study register. 204862-Switch study to evaluate dolutegravir plus lamivudine in virologically suppressed human immunodeficiency virus type 1 positive adults (TANGO)","author":"ViiV Healthcare"},{"key":"2020110510415985900_CIT0014","first-page":"132","article-title":"2017 update of the drug resistance mutations in HIV-1","volume":"24","author":"Wensing","year":"2017","journal-title":"Top Antivir Med"},{"key":"2020110510415985900_CIT0015","author":"Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services"},{"key":"2020110510415985900_CIT0016","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3851\/IMP3331","article-title":"Prevalence of pretreatment and acquired HIV-1 mutations associated with resistance to lamivudine or rilpivirine: a systematic review","volume":"24","author":"Vannappagari","year":"2019","journal-title":"Antivir Ther"},{"key":"2020110510415985900_CIT0017","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3851\/IMP3166","article-title":"Dolutegravir\/abacavir\/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, phase IIIb study","volume":"22","author":"Trottier","year":"2017","journal-title":"Antivir Ther"},{"key":"2020110510415985900_CIT0018","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/QAD.0000000000000087","article-title":"Simplification to rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants","volume":"28","author":"Palella","year":"2014","journal-title":"AIDS"},{"key":"2020110510415985900_CIT0019","author":"US Department of Health and Human Services"},{"key":"2020110510415985900_CIT0020","author":"European AIDS Clinical Society"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz1243\/32871909\/ciz1243.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/8\/1920\/34138065\/ciz1243.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/8\/1920\/34138065\/ciz1243.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T15:43:16Z","timestamp":1604590996000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/71\/8\/1920\/5697294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,6]]},"references-count":20,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,1,6]]},"published-print":{"date-parts":[[2020,11,5]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz1243","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10,15]]},"published":{"date-parts":[[2020,1,6]]}}}